Skip to main content

Figure 3.

Figure 3.

Induced pluripotent stem cells (iPSCs) derived from acute myeloid leukemia (AML) patients. AML-iPSCs do not exhibit malignant features at the undifferentiated pluripotent state, but only once they are differentiated along the hematopoietic lineage. Unlike primary AML blasts that have limited growth potential in vitro, iPSC-derived blasts can be extensively, potentially indefinitely, expanded in culture.